Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2014

Open Access 01-12-2014 | Review

Circadian rhythms in rheumatology - a glucocorticoid perspective

Authors: Cornelia M Spies, Rainer H Straub, Maurizio Cutolo, Frank Buttgereit

Published in: Arthritis Research & Therapy | Special Issue 2/2014

Login to get access

Abstract

The hypothalamic-pituitary-adrenal (HPA) axis plays an important role in regulating and controlling immune responses. Dysfunction of the HPA axis has been implicated in the pathogenesis of rheumatoid arthritis (RA) and other rheumatic diseases. The impact of glucocorticoid (GC) therapy on HPA axis function also remains a matter of concern, particularly for longer treatment duration. Knowledge of circadian rhythms and the influence of GC in rheumatology is important: on the one hand we aim for optimal treatment of the daily undulating inflammatory symptoms, for example morning stiffness and swelling; on the other, we wish to disturb the HPA axis as little as possible. This review describes circadian rhythms in RA and other chronic inflammatory diseases, dysfunction of the HPA axis in RA and other rheumatic diseases and the recent concept of the hepato-hypothalamic-pituitary-adrenal-renal axis, the problem of adrenal suppression by GC therapy and how it can be avoided, and evidence that chronotherapy with modified release prednisone effective at 02:00 a.m. can inhibit proinflammatory sequelae of nocturnal inflammation better compared with GC administration in the morning but does not increase the risk of HPA axis insufficiency in RA.
Literature
1.
go back to reference Straub RH, Cutolo M: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007, 56: 399-408. 10.1002/art.22368.CrossRefPubMed Straub RH, Cutolo M: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007, 56: 399-408. 10.1002/art.22368.CrossRefPubMed
2.
go back to reference Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F: More night than day - circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol. 2010, 37: 894-899. 10.3899/jrheum.091283.CrossRefPubMed Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F: More night than day - circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol. 2010, 37: 894-899. 10.3899/jrheum.091283.CrossRefPubMed
3.
go back to reference Sierakowski S, Cutolo M: Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl. 2011, 125: 1-5.CrossRefPubMed Sierakowski S, Cutolo M: Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl. 2011, 125: 1-5.CrossRefPubMed
4.
go back to reference Straub RH, Bijlsma JW, Masi A, Cutolo M: Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases - the 10-year update. Semin Arthritis Rheum. 2013, 43: 392-404. 10.1016/j.semarthrit.2013.04.008.CrossRefPubMed Straub RH, Bijlsma JW, Masi A, Cutolo M: Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases - the 10-year update. Semin Arthritis Rheum. 2013, 43: 392-404. 10.1016/j.semarthrit.2013.04.008.CrossRefPubMed
5.
go back to reference Cutolo M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012, 24: 312-318. 10.1097/BOR.0b013e3283521c78.CrossRefPubMed Cutolo M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012, 24: 312-318. 10.1097/BOR.0b013e3283521c78.CrossRefPubMed
6.
go back to reference Cutolo M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011, 7: 500-502. 10.1038/nrrheum.2011.115.CrossRefPubMed Cutolo M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011, 7: 500-502. 10.1038/nrrheum.2011.115.CrossRefPubMed
7.
go back to reference Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.CrossRefPubMed Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.CrossRefPubMed
8.
go back to reference Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J, Vaith P, Lang B: The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology. 2000, 39: 624-631. 10.1093/rheumatology/39.6.624.CrossRefPubMed Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J, Vaith P, Lang B: The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology. 2000, 39: 624-631. 10.1093/rheumatology/39.6.624.CrossRefPubMed
9.
go back to reference Cutolo M, Foppiani L, Minuto F: Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest. 2002, 25: 19-23. 10.1007/BF03345073.CrossRefPubMed Cutolo M, Foppiani L, Minuto F: Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest. 2002, 25: 19-23. 10.1007/BF03345073.CrossRefPubMed
10.
go back to reference Caporali R, Cimmino MA, Montecucco C, Cutolo M: Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011, 29: S143-S147.PubMed Caporali R, Cimmino MA, Montecucco C, Cutolo M: Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011, 29: S143-S147.PubMed
11.
go back to reference Bollinger T, Bollinger A, Naujoks J, Lange T, Solbach W: The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology. 2010, 131: 488-500. 10.1111/j.1365-2567.2010.03320.x.PubMedCentralCrossRefPubMed Bollinger T, Bollinger A, Naujoks J, Lange T, Solbach W: The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology. 2010, 131: 488-500. 10.1111/j.1365-2567.2010.03320.x.PubMedCentralCrossRefPubMed
12.
go back to reference Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997, 82: 1279-1283. 10.1210/jcem.82.4.3852.CrossRefPubMed Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997, 82: 1279-1283. 10.1210/jcem.82.4.3852.CrossRefPubMed
13.
go back to reference Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M: Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002, 46: 654-662. 10.1002/art.10177.CrossRefPubMed Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M: Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002, 46: 654-662. 10.1002/art.10177.CrossRefPubMed
14.
go back to reference Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol. 2003, 548: 631-638. 10.1113/jphysiol.2002.032938.PubMedCentralCrossRefPubMed Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol. 2003, 548: 631-638. 10.1113/jphysiol.2002.032938.PubMedCentralCrossRefPubMed
15.
go back to reference Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP: Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997, 66: 54-62. 10.1159/000127219.CrossRefPubMed Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP: Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997, 66: 54-62. 10.1159/000127219.CrossRefPubMed
16.
go back to reference Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993, 77: 1690-1694.PubMed Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993, 77: 1690-1694.PubMed
17.
go back to reference Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014, 73: 492-509.PubMedCentralCrossRefPubMed Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014, 73: 492-509.PubMedCentralCrossRefPubMed
18.
go back to reference Buttgereit F: Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?. Ann Rheum Dis. 2011, 70: 1881-1883. 10.1136/annrheumdis-2011-200388.CrossRefPubMed Buttgereit F: Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?. Ann Rheum Dis. 2011, 70: 1881-1883. 10.1136/annrheumdis-2011-200388.CrossRefPubMed
19.
go back to reference Narvaez J, Bernad B, Diaz Torne C, Momplet JV, Montpel JZ, Nolla JM, Valverde-Garcia J: Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006, 33: 1293-1298.PubMed Narvaez J, Bernad B, Diaz Torne C, Momplet JV, Montpel JZ, Nolla JM, Valverde-Garcia J: Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006, 33: 1293-1298.PubMed
20.
go back to reference Edwards C: Sixty years after Hench - corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab. 2012, 97: 1443-1451. 10.1210/jc.2011-2879.CrossRefPubMed Edwards C: Sixty years after Hench - corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab. 2012, 97: 1443-1451. 10.1210/jc.2011-2879.CrossRefPubMed
21.
go back to reference Charmandari E, Nicolaides NC, Chrousos GP: Adrenal insufficiency. Lancet. 2014, 383: 2152-2167. 10.1016/S0140-6736(13)61684-0.CrossRefPubMed Charmandari E, Nicolaides NC, Chrousos GP: Adrenal insufficiency. Lancet. 2014, 383: 2152-2167. 10.1016/S0140-6736(13)61684-0.CrossRefPubMed
22.
23.
go back to reference Harbuz MS, Korendowych E, Jessop DS, Crown AL, Li pdfan SL, Kirwan JR: Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/corticotrophin releasing factor test. J Endocrinol. 2003, 178: 55-60. 10.1677/joe.0.1780055.CrossRefPubMed Harbuz MS, Korendowych E, Jessop DS, Crown AL, Li pdfan SL, Kirwan JR: Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/corticotrophin releasing factor test. J Endocrinol. 2003, 178: 55-60. 10.1677/joe.0.1780055.CrossRefPubMed
24.
go back to reference Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000, 355: 542-545. 10.1016/S0140-6736(99)06290-X.CrossRefPubMed Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000, 355: 542-545. 10.1016/S0140-6736(99)06290-X.CrossRefPubMed
25.
go back to reference Klinefelter HF, Winkenwerder WL, Bledsoe T: Single daily dose prednisone therapy. JAMA. 1979, 241: 2721-2723. 10.1001/jama.1979.03290510029021.CrossRefPubMed Klinefelter HF, Winkenwerder WL, Bledsoe T: Single daily dose prednisone therapy. JAMA. 1979, 241: 2721-2723. 10.1001/jama.1979.03290510029021.CrossRefPubMed
26.
go back to reference Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, Wollheim FA: The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1415-1421. 10.1002/art.21747.CrossRefPubMed Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, Wollheim FA: The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1415-1421. 10.1002/art.21747.CrossRefPubMed
27.
go back to reference Jasani MK, Diver MJ, Bell AM, Dalakos TG, Buchanan WW: Some clinical observations on the diurnal rhythm of plasma cortisol (11-OHCS) in patients with rheumatoid arthritis treated with oral corticosteroid drugs. Curr Med Res Opin. 1974, 2: 373-386. 10.1185/03007997409112653.CrossRefPubMed Jasani MK, Diver MJ, Bell AM, Dalakos TG, Buchanan WW: Some clinical observations on the diurnal rhythm of plasma cortisol (11-OHCS) in patients with rheumatoid arthritis treated with oral corticosteroid drugs. Curr Med Res Opin. 1974, 2: 373-386. 10.1185/03007997409112653.CrossRefPubMed
28.
go back to reference Grant SD, Forsham PH, DiRaimondo VC: Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med. 1965, 273: 1115-1118. 10.1056/NEJM196511182732101.CrossRefPubMed Grant SD, Forsham PH, DiRaimondo VC: Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med. 1965, 273: 1115-1118. 10.1056/NEJM196511182732101.CrossRefPubMed
29.
go back to reference Haus E, Sackett-Lundeen L, Smolensky MH: Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications. Bull NYU Hosp Jt Dis. 2012, 70 (Suppl 1): 3-10.PubMed Haus E, Sackett-Lundeen L, Smolensky MH: Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications. Bull NYU Hosp Jt Dis. 2012, 70 (Suppl 1): 3-10.PubMed
30.
go back to reference Angeli A: Circadian ACTH-adrenal rhythm in man. Chronobiologia. 1974, 1 (Suppl 1): 253-270.PubMed Angeli A: Circadian ACTH-adrenal rhythm in man. Chronobiologia. 1974, 1 (Suppl 1): 253-270.PubMed
31.
go back to reference Nichols T, Nugent CA, Tyler FH: Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab. 1965, 25: 343-349. 10.1210/jcem-25-3-343.CrossRefPubMed Nichols T, Nugent CA, Tyler FH: Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab. 1965, 25: 343-349. 10.1210/jcem-25-3-343.CrossRefPubMed
32.
go back to reference Di Raimondo VC, Forsham PH: Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity. Am J Med. 1956, 21: 321-323. 10.1016/0002-9343(56)90033-X.CrossRefPubMed Di Raimondo VC, Forsham PH: Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity. Am J Med. 1956, 21: 321-323. 10.1016/0002-9343(56)90033-X.CrossRefPubMed
33.
go back to reference Di Raimondo VC, Forsham PH: Pharmacophysiologic principles in the use of corticoids and adrenocorticotropin. Metabolism. 1958, 7: 5-24. Di Raimondo VC, Forsham PH: Pharmacophysiologic principles in the use of corticoids and adrenocorticotropin. Metabolism. 1958, 7: 5-24.
34.
go back to reference Deandrade JR, McCormick JN, Hill AG: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis. 1964, 23: 158-162. 10.1136/ard.23.2.158.CrossRefPubMed Deandrade JR, McCormick JN, Hill AG: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis. 1964, 23: 158-162. 10.1136/ard.23.2.158.CrossRefPubMed
35.
go back to reference Smolensky MH, Peppas NA: Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007, 59: 828-851. 10.1016/j.addr.2007.07.001.CrossRefPubMed Smolensky MH, Peppas NA: Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007, 59: 828-851. 10.1016/j.addr.2007.07.001.CrossRefPubMed
37.
go back to reference De AJ: Pituitary-adrenocortical reserve during corticosteroid therapy: a report on the methopyrapone test in ten patients taking long-continued small doses. J Clin Endocrinol Metab. 1964, 24: 261-262. 10.1210/jcem-24-3-261.CrossRef De AJ: Pituitary-adrenocortical reserve during corticosteroid therapy: a report on the methopyrapone test in ten patients taking long-continued small doses. J Clin Endocrinol Metab. 1964, 24: 261-262. 10.1210/jcem-24-3-261.CrossRef
38.
go back to reference Reinberg A, Guillet P, Gervais P, Ghata J, Vignaud D, Abulker C: One month chronocorticotherapy (Dutimelan 8 15 mite). Control of the asthmatic condition without adrenal suppression and circadian rhythm alteration. Chronobiologia. 1977, 4: 295-312.PubMed Reinberg A, Guillet P, Gervais P, Ghata J, Vignaud D, Abulker C: One month chronocorticotherapy (Dutimelan 8 15 mite). Control of the asthmatic condition without adrenal suppression and circadian rhythm alteration. Chronobiologia. 1977, 4: 295-312.PubMed
39.
go back to reference McAllister WA, Mitchell DM, Collins JV: Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects. Br J Clin Pharmacol. 1981, 11: 303-304. 10.1111/j.1365-2125.1981.tb00538.x.PubMedCentralCrossRefPubMed McAllister WA, Mitchell DM, Collins JV: Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects. Br J Clin Pharmacol. 1981, 11: 303-304. 10.1111/j.1365-2125.1981.tb00538.x.PubMedCentralCrossRefPubMed
40.
go back to reference Masi AT, Chrousos GP: Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis. 1997, 56: 1-4. 10.1136/ard.56.1.1.PubMedCentralCrossRefPubMed Masi AT, Chrousos GP: Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis. 1997, 56: 1-4. 10.1136/ard.56.1.1.PubMedCentralCrossRefPubMed
41.
go back to reference Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R: The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997, 56: 27-31. 10.1136/ard.56.1.27.PubMedCentralCrossRefPubMed Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R: The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997, 56: 27-31. 10.1136/ard.56.1.27.PubMedCentralCrossRefPubMed
42.
go back to reference De Silva M, Binder A, Hazleman BL: The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis. 1984, 43: 790-793. 10.1136/ard.43.6.790.PubMedCentralCrossRefPubMed De Silva M, Binder A, Hazleman BL: The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis. 1984, 43: 790-793. 10.1136/ard.43.6.790.PubMedCentralCrossRefPubMed
43.
go back to reference Owlia MB, Mehrpoor G, Modares Mosadegh M: Bedtime single-dose prednisolone in clinically stable rheumatoid arthritis patients. ISRN Pharmacol. 2012, 2012: 637204-PubMed Owlia MB, Mehrpoor G, Modares Mosadegh M: Bedtime single-dose prednisolone in clinically stable rheumatoid arthritis patients. ISRN Pharmacol. 2012, 2012: 637204-PubMed
44.
go back to reference Karatay S, Senel K, Ugur M, Yildirim K: The timing of low dose glucocorticoid therapy in treatment of rheumatoid arthritis. Pain Clinic. 2002, 13: 305-312. 10.1163/15685690260138910.CrossRef Karatay S, Senel K, Ugur M, Yildirim K: The timing of low dose glucocorticoid therapy in treatment of rheumatoid arthritis. Pain Clinic. 2002, 13: 305-312. 10.1163/15685690260138910.CrossRef
45.
go back to reference Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG: Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol. 1981, 11: 477-484. 10.1111/j.1365-2125.1981.tb01153.x.PubMedCentralCrossRefPubMed Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG: Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol. 1981, 11: 477-484. 10.1111/j.1365-2125.1981.tb01153.x.PubMedCentralCrossRefPubMed
46.
go back to reference Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008, 371: 205-214. 10.1016/S0140-6736(08)60132-4.CrossRefPubMed Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008, 371: 205-214. 10.1016/S0140-6736(08)60132-4.CrossRefPubMed
47.
go back to reference Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1275-1280. 10.1136/ard.2009.126888.PubMedCentralCrossRefPubMed Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1275-1280. 10.1136/ard.2009.126888.PubMedCentralCrossRefPubMed
48.
go back to reference Alten R, Doring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, Buttgereit F: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010, 37: 2025-2031. 10.3899/jrheum.100051.CrossRefPubMed Alten R, Doring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, Buttgereit F: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010, 37: 2025-2031. 10.3899/jrheum.100051.CrossRefPubMed
49.
go back to reference Clarke L, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan J: Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011, 6: 241-249. 10.2217/ijr.11.12.CrossRef Clarke L, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan J: Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011, 6: 241-249. 10.2217/ijr.11.12.CrossRef
Metadata
Title
Circadian rhythms in rheumatology - a glucocorticoid perspective
Authors
Cornelia M Spies
Rainer H Straub
Maurizio Cutolo
Frank Buttgereit
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 2/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4687

Other articles of this Special Issue 2/2014

Arthritis Research & Therapy 2/2014 Go to the issue